Showing results (11-20 of 21) with videos related to
Sort By:
Pageof 3
Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova|May 23, 2012
[Adhesion molecule in the cerebrospinal fluid in multiple sclerosis]I V Smagina, A S Fedianin, S A El'chaninova, et al.Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova|June 22, 2017
[A study of the relation between the sCD40-sCD40L system and the course of multiple sclerosis]I V Smagina, O V Pereverzeva, A O Gridina, et al.Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova|June 14, 2011
[Genetic risk factors for multiple sclerosis in the population of Altay]I V Smagina, S A El'chaninova, A G Zolovkina, et al.Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova|June 16, 2017
[The association of the FAS/APO-1 (rs2234767) gene polymorphism with the risk and rapid progression of multiple sclerosis]O M Nochevnaya, O V Pereverzeva, E A Sokolova, et al.Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova|August 29, 2022
[Therapy of moderate cognitive impairment and asthenia in patients with cerebrovascular pathology: results of a prospective observational study]G I Shvartsman, A A Skoromets, S A Zhivolupov, et al.Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova|October 5, 2023
[Assessment of the efficacy and safety of alemtuzumab in patients with highly active relapsing-remitting multiple sclerosis in Russian population]S A Sivertseva, A M Prilenskaya, E V Popova, et al.Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova|January 15, 2020
[The efficacy and safety of siponimod in the Russian population of patients with secondary progressive multiple sclerosis]E P Evdoshenko, N A Neofidov, K Z Bakhtiyarova, et al.Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova|April 21, 2023
[Efficacy and safety of divozilimab during 24-week treatment of multiple sclerosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-2]A N Boyko, V M Alifirova, I G Lukashevich, et al.Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova|August 10, 2023
[Efficacy and safety of antiCD20 monoclonal antibody divozilimab during 48-week treatment of multiple sclerosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-4/MIRANTIBUS]A N Boyko, V M Alifirova, I G Lukashevich, et al.Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova|April 27, 2024
[Long-term efficacy and safety of divozilimab during 2-year treatment of multiple sclerosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-4/MIRANTIBUS]A N Boyko, V M Alifirova, I G Lukashevich, et al.Pageof 3